Who
Jay Venkatesan
Director
Company insider
Files Form 4 as: Director and Officer, Elicio Therapeutics; Director, Serina Therapeutics; President, Alpine Immune Sciences; Director, Exicure; Director and 10% owner, Iovance Biotherapeutics; EVP and General Manager, Oncothyreon; Director, Targanta Therapeutics.
In numbers
- Trades disclosed
- 109
- Buys
- 15
- Sells
- 3
- Bought
- $9.1M
- Sold
- $8.9M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 15 Oct 2007
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 31 Aug 2026filed 2 Sep 2026 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,750 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $504K224,152 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,250 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | $217K96,525 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | $217K96,525 at $2.25 | filing |
| 17 Jun 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code C | $504K224,152 at $2.25 | filing |
| 22 May 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,048589 at $1.78 | filing |
| 22 May 2026filed 22 Jun 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,048589 at $1.78 | filing |
| 31 Mar 2026filed 21 Apr 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K7,553 at $1.94 | filing |
| 31 Mar 2026filed 21 Apr 2026 | SER Serina TherapeuticsBiotechnology | SEC FORM 4 Code A | $15K7,553 at $1.94 | filing |
| 7 Nov 2025filed 10 Nov 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 May 2025filed 20 May 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,900 at $0.00 | filing |
| 8 Apr 2025filed 10 Apr 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $500K96,525 at $5.18 | filing |
| 12 Feb 2025filed 13 Feb 2025 | SER Serina Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Nov 2024filed 29 Nov 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code X | —50,000 at $0.00 | filing |
| 26 Nov 2024filed 29 Nov 2024 | ELTX Elicio TherapeuticsBiotechnology | SEC FORM 4 Code X | $50050,000 at $0.01 | filing |
| 21 Nov 2024filed 25 Nov 2024 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 28 Jun 2024filed 2 Jan 2025 | ELTX Elicio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —50,000 at $0.00 | filing |
News
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Stock Short Interest Report for SeptemberSER · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Jay Venkatesan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.